纳武利尤单抗治疗非小细胞肺癌脑转移的疗效:回顾性研究
该回顾性研究收集22例接受纳武利尤单抗单药治疗的NSCLC脑转移患者,21例可评价颅内疗效,颅内客观缓解率28.6%,颅内疾病控制率47.6%,中位颅内无进展生存5.2个月,1年与2年生存率均为56.7%。结论认为PD-1单抗对NSCLC脑转移患者的疗效可能与无脑转移者相似。
要点
- 纳武利尤单抗治疗NSCLC脑转移的颅内客观缓解率为28.6%。
- 颅内疾病控制率为47.6%,中位颅内无进展生存5.2个月。
- 1年与2年生存率均为56.7%,疗效可能与无脑转移者相似。
核心结论
- NSCLC脑转移患者接受PD-1单抗治疗,可能与无脑转移者疗效相似。
研究设计与样本
- 回顾性研究,收集22例经纳武利尤单抗单药治疗的NSCLC脑转移患者的临床病理资料。
- 通过电子影像学资料阅片确认疗效及疾病进展时间,随访获取生存资料。
主要发现
- 21例患者可进行颅内疗效评价,颅内客观缓解率为28.6%,颅内疾病控制率为47.6%。
- 22例患者的中位颅内无进展生存时间为5.2个月。
- 1年与2年生存率均为56.7%。
临床怎么用
- 对于NSCLC脑转移患者,纳武利尤单抗单药治疗可作为一种治疗选择,需结合颅内疗效与生存数据综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To preliminarily explore the treatment effect of nivolumab on Chinese non-small-cell lung cancer (NSCLC) patients with brain metastases, and further enrich the evidences of programmed death-ligand 1 (PD-1) monoclonal antibody in the treatment of NSCLC patients with brain metastases. Methods: The clinical and pathological data of 22 NSCLC patients with brain metastases treated with nivolumab were collected. The electronic imaging data were collected to confirm the treatment effect and time point of disease progression, and the survival data of the patients were obtained through follow-up. Results: Twenty-one patients were evaluated for the intracranial treatment effect. The intracerebral objective response rate (IORR) was 28.6%, the intracranial disease control rate (IDCR) was 47.6%. The median intracranial progression-free-survival (iPFS) of all the 22 patients was 5.2 months. Both the 1-year and 2-year survival rates were 56.7%. Conclusions: The treatment effect of PD-1 monoclonal antibody on NSCLC patients with brain metastases is similar as those without brain metastases. 目的: 初步了解纳武利尤单抗对非小细胞肺癌(NSCLC)脑转移的疗效,进一步充实中国PD-1单抗治疗NSCLC脑转移的证据。 方法: 收集22例经纳武利尤单抗单药治疗的NSCLC脑转移患者的临床病理资料,调取电子影像学资料阅片,确认疗效及疾病进展时间,随访获取患者生存资料。 结果: 21例患者可进行颅内疗效评价,颅内客观缓解率为28.6%,颅内疾病控制率为47.6%。22例患者的中位颅内无进展生存时间为5.2个月,1、2年生存率均为56.7%。 结论: NSCLC脑转移患者接受PD-1单抗治疗,可能与无脑转移者疗效相似。.
引用
- Zhang GW, Cheng RR, Wang HJ, et al. [Therapeutic effect of nivolumab on non-small-cell lung cancer patients with brain metastases: a retrospective study]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33256309. doi:10.3760/cma.j.cn112152-20190130-00059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。